title: Comparison of the therapeutic efficacy of 211At- and 131I-labelled monoclonal antibody MOv18 in nude mice with intraperitoneal growth of human ovarian cancer.
abstract: The purpose of the present study was to compare the therapeutic efficacy of the alpha-emitter Astatine-211 with the beta-emitter Iodine-131 bound to the specific monoclonal antibody MOv18. The measurements were performed in an ovarian cancer cell line (NIH:OVCAR 3) growing intraperitoneally in nude mice. Two weeks after the intraperitoneal inoculation of 1 x 10(7) cells of the human ovarian cancer cell line NIH:OVCAR-3 twenty mice were treated intraperitoneally with the specific monoclonal antibody MOv-18 labelled with either 211At (310-400 kBq) or 131I (5100-6200 kBq). The pharmacokinetics and biodistribution of labelled antibody in tumour-free animals were studied and the resulting bone marrow dose was estimated. When the mice were treated with 211At-labelled antibody 9 out of 10 mice were free of macro- and microscopic tumour compared to 3 out of 10 when Iodine-131 was used. The equivalent dose to the bone marrow was 2.4-3.1 Sv from 211At- and 3.4-4.1 Sv from 131I-irradiation. The therapeutic efficacy of 211At-labelled specific antibody is very good and, at approximately equivalent bone marrow doses, better than that of 131I.
authors: Department of Gynaecological Oncology, Sahlgrenska University Hospital, Gothenburg, Sweden.
authors: H
authors: H
authors: Andersson
authors: S
authors: S
authors: Palm
authors: S
authors: S
authors: Lindegren
authors: T
authors: T
authors: Bäck
authors: L
authors: L
authors: Jacobsson
authors: G
authors: G
authors: Leser
authors: G
authors: G
authors: Horvath
mesh_terms: D000512:Alpha Particles / Q000627:therapeutic use; D000818:Animals; D000911:Antibodies, Monoclonal / Q000493:pharmacokinetics / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D001246:Astatine / Q000627:therapeutic use*; D001610:Beta Particles / Q000627:therapeutic use; D001853:Bone Marrow / Q000528:radiation effects; D002455:Cell Division / Q000528:radiation effects; D005260:Female; D006801:Humans; D018796:Immunoconjugates / Q000493:pharmacokinetics / Q000627:therapeutic use*; D007457:Iodine Radioisotopes / Q000627:therapeutic use; D051379:Mice; D008819:Mice, Nude; D010051:Ovarian Neoplasms / Q000378:metabolism / Q000473:pathology / Q000532:radiotherapy*; D010534:Peritoneal Neoplasms / Q000378:metabolism / Q000532:radiotherapy* / Q000556:secondary; D016499:Radioimmunotherapy; D011879:Radiotherapy Dosage; D014407:Tumor Cells, Cultured
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D018796:Immunoconjugates; D007457:Iodine Radioisotopes; C424863:MOv18 monoclonal antibody; D001246:Astatine